Pharmacogenomics in 2026: From Research Concept to Clinical Workflow
Pharmacogenomics has officially left the lab bench, transitioning from niche research to a central pillar of clinical practice in 2026. Major healthcare systems, spearheaded by institutions like Mayo Clinic and Vanderbilt, are now routinely integrating germline genetic data into electronic health records to guide prescribing decisions, effectively reducing adverse drug reactions and boosting therapeutic efficacy across oncology, cardiology, and psychiatry. This systemic shift is being driven by maturing interoperability standards and advanced clinical decision support systems.















